Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19

Edward Needham1,3 · Virginia Newcombe1,2 · Andrew Michell1 · Rachel Thornton1 · Andrew Grainger1 · Fahim Anwar1 · Elizabeth Warburton1,3 · David Menon1,2,3 · Monica Trivedi1 · Stephen Sawcer1,3

Received: 1 October 2020 / Revised: 2 November 2020 / Accepted: 15 November 2020 / Published online: 26 November 2020
© The Author(s) 2020

Abstract
The prolonged mechanical ventilation that is often required by patients with severe COVID-19 is expected to result in significant intensive care unit-acquired weakness (ICUAW) in many of the survivors. However, in our post-COVID-19 follow-up clinic we have found that, as well as the anticipated global weakness related to loss of muscle mass, a significant proportion of these patients also have disabling focal neurological deficits relating to multiple axonal mononeuropathies. Amongst the 69 patients with severe COVID-19 that have been discharged from the intensive care units in our hospital, we have seen 11 individuals (16%) with such a mononeuritis multiplex. In many instances, the multi-focal nature of the weakness in these patients was initially unrecognised as symptoms were wrongly assumed to relate simply to “critical illness neuromyopathy”. While mononeuropathy is well recognised as an occasional complication of intensive care, our experience suggests that such deficits are surprisingly frequent and often disabling in patients recovering from severe COVID-19.

Keywords COVID-19 · Neuropathy · Nerve injury · Mononeuritis multiplex

Introduction and case series
The respiratory manifestations of the COVID-19 pandemic have strained health-care systems around the world [1]. Thousands of patients have required prolonged periods of mechanical ventilation and many are inevitably emerging with significant “intensive care unit-acquired weakness” (ICUAW) [2, 3]. Amongst the COVID-19 survivors attending our ICU follow-up clinic we have noticed that, in addition to the anticipated symmetrical weakness related to sarcopaenia [4], a significant number of these patients also have marked focal neurological deficits related to superimposed mononeuropathies. Here we present the findings in the first 11 such patients that we have seen (Fig. 1 and Table 1), many of whom are significantly disabled by their neuropathies.

All these patients had severe COVID-19 necessitating mechanical ventilation for an average of 36 days (range 16–73), five required periods of prone positioning, and one required extra-corporeal membrane oxygenation (ECMO). Eight of the 11 were men (representative of the known sex difference for severe disease), and the median age was 58 years (range 50–77). Four of the patients had type 2 diabetes (none on insulin) and most were overweight, the mean baseline BMI being 28 (range 21–53). The neuropathies were noted following withdrawal of sedation, indicating that these nerve injuries developed during the period of ventilation. The clinical deficits have been static or improving when reviewed serially during convalescence, suggesting that the active disease process was limited to the acute phase. In several of the patients, the neuropathies substantially prolonged the need for inpatient rehabilitation and delayed hospital discharge.

All of the patients had evidence of a modest global symmetrical weakness consistent with the sarcopaenia that would be expected following severe critical illness, but none showed electromyographic (EMG) evidence of myopathy. Similarly, only one of the patients showed evidence of
At the time of writing, 102 COVID-19-positive patients have been treated in the ICUs in our hospital, 44 of these have been discharged home, 14 have been transferred to other hospitals for further rehabilitation, 11 are still recovering in our hospital and 33 have died. Not all of the discharged patients have yet been seen for follow-up so additional cases of mononeuropathy may still come to light. Whilst mononeuropathies are a well-recognised complication of anaesthesia and intensive care [2], the number of affected patients (at least 16% of those discharged from ICU in our hospital), the number of nerves affected in each patient (an average of just over 3 per patient), and the particular nerves involved (such as the proximal sciatic) are all outside common experience. There have been previous descriptions of bilateral sciatic neuropathies resulting from intensive care, with the patient initially being mistakenly thought to have critical illness neuropathy, but such patients are sufficiently uncommon to warrant individual case reports [6].

**Discussion**

This series of cases highlights an important neurological complication occurring frequently in patients with severe COVID-19, which detrimentally affects long-term outcomes and markedly influences their rehabilitation needs. Given that, this complication is evident in a significant proportion of the patients discharged from the intensive care units of a single hospital (16% in our cohort of treated patients) and the rehabilitation burden globally could be substantial. Furthermore, given the high expectation of ICUAW, these focal deficits may go unnoticed.

The underlying aetiology of these neuropathies remains to be established. Mechanical factors related to patient handling and positioning are recognised to occasionally cause focal neuropathy [7], raising the possibility that perhaps patients with severe COVID-19 are very much more susceptible to such nerve injuries. Against this, we saw no evidence for the demyelinating features typically seen in such injuries, and many of our patients had neuropathies at sites that would be highly unusual for compression or traction (including musculocutaneous, proximal median and high sciatic neuropathies). From a clinical and electrophysiological perspective, the neurological deficits we have seen in our patients have much in common with vasculitic neuropathies such as lumbar sacral radiculoplexus neuropathy (Bruns–Garland syndrome) and brachial neuritis (Parsonage–Turner syndrome) [8]. However, these syndromes are usually, but not always, preceded by considerable pain, which was not a common feature in our cohort. However, since our patients developed their deficits while they were sedated and ventilated, this phase of the illness was necessarily obscured.
Furthermore, post-mortem studies have confirmed that vasculitis is prominent in a range of tissues in patients dying from COVID-19, although peripheral nerve tissue has not yet been specifically examined [9]. The aetiology of this vasculitis is also uncertain, but might relate to an endotheliopathy [10] resulting from the “cytokine storm” that is so characteristic of these patients [11], or perhaps the microthrombi [12] that are known to frequently occur in COVID-19. The elevations of Interleukin 6 and d-dimer seen in these patients are in keeping with these respective processes, but the broad ranges seen do not clearly support one above the other.

In summary, we have observed a mononeuritis multiplex in a significant fraction of the patients with severe COVID-19 that were admitted to the intensive care units of our hospital. While we recognise this is a small number of individuals in total, and that we have no direct comparative group to demonstrate that this phenomenon is unique to COVID-19, the clinical features are striking and their implications for rehabilitation profound. We strongly urge detailed neurological assessment of patients with post-COVID-19 ICUAW, especially those with asymmetric weakness, as we suspect that many such patient are likely to have focal deficits.

Acknowledgements The authors thank Jon Curtis for his help in designing and constructing the figure.

Author contributions All authors contribute to the clinical care of the patients described and all provided substantive input to the design, drafting and editing of the manuscript.

Funding This work was supported by the Cambridge NIHR Biomedical Research Centre.

Availability of data and material All available data are included in the paper.

**Compliance with ethical standards**

Conflicts of interest/competing The authors declare that they have no competing interest.

Ethics approval The study was approved by the Cambridge University Hospitals Research and Development office.

Consent to participate Not applicable (this is not an interventional study).

Consent for publication All patients gave fully informed written consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. WHO Situation report 157. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ Accessed 26 June 2020
2. Zhou C, Wu L, Ni F, Ji W, Wu J, Zhang H (2014) Critical illness polyneuropathy and myopathy: a systematic review. Neural Regen Res 9:101–110. https://doi.org/10.4103/1673-5374.125337
3. Madia F, Merico B, Primiano G, Cutuli SL, De Pascale G, Servidei S (2020) Acute myopathic quadriplegia in COVID-19 patients in the intensive care unit. Neurology. 95:492–494. https://doi.org/10.1212/WNL.000000000000010280
4. Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M (2016) Sar-
copenia in critically ill patients. J Anesth 30:884–890. https :/ /doi. 
org/10.1007/s00540-016-2211-4
5. EFNS Task Force European Federation of Neurological Soci-
eties/Peripheral Nerve Society Guideline on management of 
chronic inflammatory demyelinating polyradiculoneuropathy 
(2010) Report of a joint task force of the European Federation 
of Neurological Societies and the Peripheral Nerve Society -First 
Revision. Eur J Neuro 17:356–63. https :/ /doi.org/10.111 
1/j.1468-1331.2009.02930.x
6. Zambelis T, Giotopoulou D, Soldatos T et al (2015) Bilateral sci-
atic neuropathy misdiagnosed as critical illness neuropathy: a case 
report. Neurol Sci 36:1707–1708. https :/ /doi.org/10.1007/s1007 
2-015-2241-y
7. Kwee MM, Ho YH, Rozen WM (2015) The prone position during 
surgery and its complications: a systematic review and evidence-
based guidelines. Int Surg 100:292–303. https :/ /doi.org/10.9738/ 
INTSURG-D-13-00256.1
8. Gwathmey KG, Burns TM, Collins MP et al (2014) Vasculitic 
neuropathies. Lancet Neurol 13:67–82. https :/ /doi.org/10.1016/ 
S1474-4422(13)70236-9
9. Dorward DA, Russell CD, Uma IH et al (2020) Tissue-
specific tolerance in fatal Covid-19. medRxiv. https :/ /doi. 
org/10.1101/2020.07.02.20145003
10. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, 
Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch 
H (2020) Endothelial cell infection and endotheliitis in COVID-
19. Lancet 395(10234):1417–1418. https :/ /doi.org/10.1016/S0140 
-6736(20)30937-5
11. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Man-
son JJ (2020) COVID-19: consider cytokine storm syndromes 
and immunosuppression. Lancet 395:1033–1034. https :/ /doi. 
org/10.1016/S0140-6736(20)30628-0
12. McFadyen JD, Stevens H, Peter K (2020) The emerging threat of 
(Micro) thrombosis in COVID-19 and its therapeutic implications. 
Circ Res 127:571–587. https :/ /doi.org/10.1161/CIRCRESAHA .120.317447

 Springer